

Dominik Wolf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12089798/publications.pdf>

Version: 2024-02-01

128
papers

9,021
citations

57758

44
h-index

42399

92
g-index

131
all docs

131
docs citations

131
times ranked

13351
citing authors

#	ARTICLE	IF	CITATIONS
1	Hairy Cell Leukemia Patients Have a Normal Life Expectancyâ€”A 35-Year Single-Center Experience and Comparison with the General Population. <i>Cancers</i> , 2022, 14, 1242.	3.7	8
2	Austrian recommendations for the management of essential thrombocythemia. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 52-61.	1.9	2
3	Helios-expressing CD8 ⁺ T cells are decreased in patients with systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 1022-1024.	1.6	4
4	ENVIRONMENTAL Aspects in Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5202.	4.1	0
5	Fecal microbiota transfer for refractory intestinal graft-versus-host disease â€” Experience from two German tertiary centers. <i>European Journal of Haematology</i> , 2021, 107, 229-245.	2.2	20
6	The Biology of Classic Hairy Cell Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7780.	4.1	8
7	Tumor rejection in <i>Cblb</i> ^{hi} mice depends on IL-9 and Th9 cells. , 2021, 9, e002889.		11
8	Pacritinib protects dendritic cells more efficiently than ruxolitinib. <i>Experimental Hematology</i> , 2021, 100, 37-40.	0.4	3
9	NK Cells in Myeloproliferative Neoplasms (MPN). <i>Cancers</i> , 2021, 13, 4400.	3.7	0
10	ROCKing Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01081.	1.6	1
11	High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. <i>International Journal of Cancer</i> , 2020, 146, 2007-2018.	5.1	38
12	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i> Internal Tandem Duplication Mutation (SORMAIN). <i>Journal of Clinical Oncology</i> , 2020, 38, 2993-3002.	1.6	335
13	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000942.	4.5	26
14	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. <i>Molecular Cancer</i> , 2020, 19, 141.	19.2	141
15	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	4.5	64
16	Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102948.	4.4	21
17	Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and Tj ETQq1 1 0.784314 rgBT/Overlock 10 Tf 50 Haematology,the, 2020, 7, e196-e208.	4.6	199
18	The Role of Immune Checkpoints after Cellular Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3650.	4.1	7

#	ARTICLE	IF	CITATIONS
19	Fibroblasts in cancer: Defining target structures for therapeutic intervention. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 111-121.	7.4	14
20	Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4233.	4.1	44
21	Ovarian Cancer Stem Cell Heterogeneity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 201-221.	1.6	27
22	The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1662-1667.	2.4	22
23	Low-dose vemurafenib in hairy cell leukemia patients with active infection. <i>American Journal of Hematology</i> , 2019, 94, E180-E182.	4.1	27
24	Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes <i>Aspergillus</i> outgrowth. <i>Blood Advances</i> , 2019, 3, 1695-1700.	5.2	19
25	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	1.4	228
26	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
27	(Iso)form Matters: Differential Implication of Vav3 Variants in Ovarian Cancer. <i>Oncologist</i> , 2018, 23, 757-759.	3.7	4
28	Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haematopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. <i>Lancet Haematology</i> , 2018, 5, e201-e210.	4.6	44
29	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
30	Intravesical cidofovir application in BK virus cystitis after allogeneic hematopoietic stem cell transplantation (HSCT) is safe and highly effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 495-498.	2.4	10
31	Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum response. <i>International Journal of Cancer</i> , 2018, 142, 1640-1651.	5.1	8
32	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 1668-1679.	10.7	250
33	Evaluation of Vav3.1 as prognostic marker in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2067-2076.	2.5	9
34	Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. <i>European Journal of Haematology</i> , 2018, 101, 305-317.	2.2	39
35	Recommendations for the diagnosis and treatment of patients with polycythaemia vera. <i>European Journal of Haematology</i> , 2018, 101, 654-664.	2.2	11
36	Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor. <i>Recent Results in Cancer Research</i> , 2018, 212, 87-108.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Long-Term Efficacy and Safety of Ropoginterferon Alfa-2b in Patients with Polycythemia Vera â€” Final Phase I/II Peginvera Study Results. <i>Blood</i> , 2018, 132, 3030-3030.	1.4	12
38	Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. <i>Gut</i> , 2017, 66, 145-155.	12.1	58
39	JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 88-96.	3.2	29
40	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. <i>Leukemia Research</i> , 2017, 59, 47-54.	0.8	58
41	<scp>JAK</scp> inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2017, 26, 728-730.	2.9	42
42	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 175-184.	1.6	36
43	Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. <i>Scientific Reports</i> , 2017, 7, 13012.	3.3	9
44	Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	3
45	Antigen-presenting human B cells are expanded in inflammatory conditions. <i>Journal of Leukocyte Biology</i> , 2017, 101, 577-587.	3.3	28
46	Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2291.	4.1	40
47	Optimized Stem Cell Detection Using the DyeCycle-Triggered Side Population Phenotype. <i>Stem Cells International</i> , 2016, 2016, 1-14.	2.5	22
48	Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFNâ€alpha in a patient with newly diagnosed ALL. <i>European Journal of Haematology</i> , 2016, 97, 208-210.	2.2	27
49	Get a grip on immune cells by inhibiting JAKs. <i>Oncolimmunology</i> , 2016, 5, e1071009.	4.6	4
50	Ionophore Antibiotics as Cancer Stem Cell-Selective Drugs: Open Questions. <i>Oncologist</i> , 2016, 21, 1291-1293.	3.7	15
51	Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. <i>Cytotherapy</i> , 2016, 18, 1325-1331.	0.7	33
52	Iron deficiency or anemia of inflammation?. <i>Wiener Medizinische Wochenschrift</i> , 2016, 166, 411-423.	1.1	100
53	Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 276-289.	7.4	42
54	<scp>OCTET</scp>â€<scp>CY</scp>: a phase <scp>II</scp> study to investigate the efficacy of postâ€transplant cyclophosphamide as sole graftâ€versusâ€host prophylaxis after allogeneic peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 27-35.	2.2	52

#	ARTICLE	IF	CITATIONS
55	Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors. <i>Oncolmunology</i> , 2016, 5, e1065368.	4.6	12
56	JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1281-1283.	0.7	68
57	High prevalence of side population in human cancer cell lines. <i>Oncoscience</i> , 2016, 3, 85-87.	2.2	12
58	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. <i>Blood</i> , 2015, 125, 901-906.	1.4	239
59	Ropeginterferon alfa-2b, a novel IFN γ -2b, induces high response rates with low toxicity in patients with polycythemia vera. <i>Blood</i> , 2015, 126, 1762-1769.	1.4	142
60	Another piece of the puzzle – optimal <sc>TKI</sc> selection before treatment discontinuation in <sc>CML</sc>. <i>European Journal of Haematology</i> , 2015, 94, 189-190.	2.2	0
61	Secretoneurin gene therapy improves hind limb and cardiac ischaemia in Apo E \sim / \sim mice without influencing systemic atherosclerosis. <i>Cardiovascular Research</i> , 2015, 105, 96-106.	3.8	14
62	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg α -interferon alpha α 2b. <i>American Journal of Hematology</i> , 2015, 90, 288-294.	4.1	44
63	Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions – A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 653-660.	2.0	163
64	Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. <i>Frontiers in Oncology</i> , 2015, 5, 58.	2.8	64
65	Treg(s) in Cancer: Friends or Foe?. <i>Journal of Cellular Physiology</i> , 2015, 230, 2598-2605.	4.1	105
66	JAK1/2 inhibition impairs T cell function <i>in vitro</i> and in patients with myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2015, 169, 824-833.	2.5	136
67	JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. <i>Cancer Research</i> , 2015, 75, 2187-2199.	0.9	163
68	CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies – Immuno-oncology Advances Clinical Cancer Research. <i>Clinical Cancer Research</i> , 2015, 21, 2657-2659.	7.0	4
69	Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics. <i>Stem Cells Translational Medicine</i> , 2015, 4, 1028-1032.	3.3	30
70	Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2315-2325.	1.3	19
71	Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Pegivera Stud. <i>Blood</i> , 2015, 126, 1603-1603.	1.4	1
72	NK cell modulation by JAK inhibition. <i>Oncoscience</i> , 2015, 2, 677-678.	2.2	8

#	ARTICLE	IF	CITATIONS
73	The E3 Ubiquitin Ligase Cbl-b Limits Nascent Th9 Differentiation. <i>Blood</i> , 2015, 126, 2222-2222.	1.4	0
74	The JAK Inhibitor Ruxolitinib Impairs Dendritic Cell Migration Via Off-Target Inhibition of Rock. <i>Blood</i> , 2015, 126, 3423-3423.	1.4	0
75	Medical decision analysis for first-line therapy of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1758-1767.	1.3	4
76	Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2 . <i>EMBO Molecular Medicine</i> , 2014, 6, 810-820.	6.9	29
77	Implementing combinatorial immunotherapeutic regimens against cancer. <i>Oncolmmunology</i> , 2014, 3, e27588.	4.6	13
78	Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib. <i>New England Journal of Medicine</i> , 2014, 371, 2537-2538.	27.0	128
79	The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. <i>Nature</i> , 2014, 507, 508-512.	27.8	394
80	Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. <i>Lung Cancer</i> , 2014, 85, 81-87.	2.0	44
81	The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics. <i>Oncotarget</i> , 2014, 5, 7027-7039.	1.8	75
82	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. <i>Blood</i> , 2014, 124, 1800-1800.	1.4	5
83	Negligible Nuclear FOXP3 Expression in Breast Cancer Epithelial Cells Compared With FOXP3-Positive T Cells. <i>Clinical Breast Cancer</i> , 2013, 13, 264-270.	2.4	10
84	Engineering effective T-cell based antitumor immunity. <i>Oncolmmunology</i> , 2013, 2, e22893.	4.6	6
85	The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. <i>Blood</i> , 2013, 122, 1192-1202.	1.4	300
86	Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?. <i>Blood</i> , 2013, 122, 3843-3844.	1.4	139
87	The Role of the E3 Ligase Cbl-B in Murine Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e65178.	2.5	14
88	Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML. <i>Blood</i> , 2013, 122, 257-257.	1.4	41
89	Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study. <i>Blood</i> , 2013, 122, 4046-4046.	1.4	6
90	Reinforcement of cancer immunotherapy by adoptive transfer of $\text{Cblb}^{-/-}$ deficient CD8 ⁺ T cells combined with a DC vaccine. <i>Immunology and Cell Biology</i> , 2012, 90, 130-134.	2.3	22

#	ARTICLE	IF	CITATIONS
91	Releasing the Brake: Targeting Cbl-b to Enhance Lymphocyte Effector Functions. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-5.	3.3	36
92	High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial. <i>Haematologica</i> , 2012, 97, 1562-1569.	3.5	10
93	Novel treatment concepts for graft-versus-host disease. <i>Blood</i> , 2012, 119, 16-25.	1.4	70
94	High transforming growth factor $\beta 2$ expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. <i>Human Pathology</i> , 2012, 43, 339-349.	2.0	40
95	Adoptive Transfer of siRNA Cblb-Silenced CD8+ T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model. <i>PLoS ONE</i> , 2012, 7, e44295.	2.5	51
96	DyeCycle violet used for side population detection is a substrate of P-glycoprotein. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 517-522.	1.5	24
97	Ex vivo leukemia models and their potential clinical relevance. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 68-69.	0.6	0
98	Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?. <i>Expert Review of Hematology</i> , 2011, 4, 153-159.	2.2	3
99	Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. <i>Blood</i> , 2011, 118, 4977-4984.	1.4	179
100	Potential Role of Regulatory T Cells in Reversing Obesity-Linked Insulin Resistance and Diabetic Nephropathy. <i>Diabetes</i> , 2011, 60, 2954-2962.	0.6	262
101	IL-9 Production by Regulatory T Cells Recruits Mast Cells That Are Essential for Regulatory T Cell-Induced Immune Suppression. <i>Journal of Immunology</i> , 2011, 186, 83-91.	0.8	160
102	High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. <i>Haematologica</i> , 2010, 95, 908-913.	3.5	28
103	Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1813-1823.	4.2	3
104	First annual report of the Austrian CML registry. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 558-566.	1.9	4
105	The Neuropeptide Catestatin Acts As a Novel Angiogenic Cytokine via a Basic Fibroblast Growth Factor-Dependent Mechanism. <i>Circulation Research</i> , 2010, 107, 1326-1335.	4.5	93
106	The Role of Missing Killer Cell Immunoglobulin-Like Receptor Ligands in T Cell Replete Peripheral Blood Stem Cell Transplantation from HLA-Identical Siblings. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 273-280.	2.0	25
107	The Sphingosine 1-Phosphate Receptor Agonist FTY720 Potently Inhibits Regulatory T Cell Proliferation In Vitro and In Vivo. <i>Journal of Immunology</i> , 2009, 183, 3751-3760.	0.8	56
108	Gene Therapy With the Angiogenic Cytokine Secretoneurin Induces Therapeutic Angiogenesis by a Nitric Oxide-Dependent Mechanism. <i>Circulation Research</i> , 2009, 105, 994-1002.	4.5	47

#	ARTICLE	IF	CITATIONS
109	Intratumoral interferon regulatory factor (IRF)â€1 but not IRFâ€2 is of relevance in predicting patient outcome in ovarian cancer. <i>International Journal of Cancer</i> , 2009, 124, 2353-2360.	5.1	29
110	A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours. <i>Drug Safety</i> , 2009, 32, 1001-1015.	3.2	14
111	Mesenchymal stem cells as cellular immunosuppressants. <i>Lancet, The</i> , 2008, 371, 1553-1554.	13.7	43
112	Role of Forkhead Box Protein 3 Expression in Invasive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4499-4500.	1.6	20
113	Regulatory T-Cells in the Graft and the Risk of Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation. <i>Transplantation</i> , 2007, 83, 1107-1113.	1.0	84
114	Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 549-554.	2.1	59
115	Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. <i>Journal of Hepatology</i> , 2006, 44, 537-543.	3.7	88
116	Telomere length of in vivo expanded CD4+CD25+ regulatory T-cells is preserved in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1198-1208.	4.2	29
117	CD34+/CD133â€ circulating endothelial precursor cells (CEP): Characterization, senescence and in vivo application. <i>Experimental Gerontology</i> , 2006, 41, 600-608.	2.8	32
118	CD4+CD25+ regulatory T cells: A new treatment option in glomerulonephritis. <i>Kidney International</i> , 2005, 68, 1898-1899.	5.2	5
119	RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. <i>Experimental Hematology</i> , 2005, 33, 767-775.	0.4	68
120	Dendritic cells from patients with chronic myeloid leukemia: Functional and phenotypic features. <i>Leukemia and Lymphoma</i> , 2005, 46, 663-670.	1.3	18
121	The kinase inhibitor imatinib mesylate inhibits TNF-Î± production <i>in vitro</i> and prevents TNF-dependent acute hepatic inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 13622-13627.	7.1	121
122	The Expression of the Regulatory T Cellâ€Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 8326-8331.	7.0	474
123	CD4+CD25+ Regulatory T Cells Inhibit Experimental Anti-Glomerular Basement Membrane Glomerulonephritis in Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1360-1370.	6.1	168
124	Endothelial progenitor cells: A source for therapeutic vasculogenesis?. <i>Journal of Cellular and Molecular Medicine</i> , 2004, 8, 509-518.	3.6	74
125	Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 630-635.	2.1	682
126	Increase of regulatory T cells in the peripheral blood of cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 606-12.	7.0	618

#	ARTICLE	IF	CITATIONS
127	Low-molecular-weight hyaluronic acid induces nuclear factor- κ B-dependent resistance against tumor necrosis factor α -mediated liver injury in mice. <i>Hepatology</i> , 2001, 34, 535-547.	7.3	49
128	Importance of Kupffer Cells for T-Cell-Dependent Liver Injury in Mice. <i>American Journal of Pathology</i> , 2000, 157, 1671-1683.	3.8	270